Deep Learning in Gynecologic Cancer Diagnosis: Current Advances, Challenges, and Future Directions

Anonymous Author(s) Affiliation Address email

Abstract

Gynecologic cancers pose significant global health challenges, especially in low-1 resource settings with limited diagnostic expertise. Deep learning (DL) presents 2 a promising avenue for automating image analysis, offering more consistent and 3 accurate diagnoses. This review assesses current DL applications, challenges, and 4 future prospects in gynecologic cancer diagnosis across diverse imaging modalities. 5 Following PRISMA-2 guidelines, a literature review evaluated studies utilizing 6 DL for diagnosing gynecologic cancers via MRI, CT scans, Pap smears, and 7 colposcopy. Data extraction and quality assessment were conducted using the 8 QUADAS-2 tool, with diagnostic performance evaluated using R software. Of 48 9 reviewed studies, 24 met inclusion criteria for meta-analysis. DL models, primarily 10 ResNet, VGGNet, and UNet, demonstrated higher sensitivity (89.40%) but slightly 11 lower specificity (87.6%) compared to traditional machine learning (ML) methods 12 (sensitivity: 68.1%, specificity: 94.1%). DL models exhibited an AUC of 0.88, 13 indicating high diagnostic accuracy. Challenges including study heterogeneity 14 and methodological biases highlight the need for standardized protocols. Despite 15 obstacles, DL shows promise in gynecologic cancer diagnosis, particularly in 16 resource-limited settings. Addressing these challenges can enhance DL's clinical 17 utility and improve patient outcomes. 18

19 1 Introduction

Gynecologic cancers, including cervical, ovarian, and endometrial cancers, pose significant health
risks to women globally, especially in low-resource settings[11, 2, 3]. Traditional diagnostic methods
relying on human interpretation are inconsistent and error-prone [2, 3, 7]. Recent advances in DL
offer automated, consistent, and precise diagnostic capabilities using medical images [5, 10, 1, 12,
8, 4, 6]. This paper reviews recent DL applications in gynecologic cancer diagnosis, discusses their
performance compared to conventional methods, and highlights future research directions aimed at
overcoming current challenges.

27 2 Methods

A systematic review and meta-analysis following PRISMA-2[9] guidelines were conducted. The 28 protocol was registered in PROSPERO under registration number 356104. We searched databases 29 including PubMed, Embase, and Scopus for articles published between January 2018 and December 30 2022, focusing on DL applications for diagnosing several gynecologic cancers. Articles were screened 31 and assessed using QUADAS-2 [13] for eligibility and quality. Data on diagnostic performance 32 33 metrics, specifically sensitivity and specificity, were extracted and analyzed using the "meta" and "mada" packages. Pooled sensitivity, specificity, summary receiver operating characteristic (SROC) 34 curves, and area under the curve (AUC) metrics were calculated using R software. 35

Submitted to 38th Conference on Neural Information Processing Systems (NeurIPS 2024). Do not distribute.

36 3 Experimental Results

³⁷ The review included 48 studies, with 24 studies eligible for meta-analysis. The imaging modalities

- used across these studies included cytology (20 studies), colposcopy (15 studies), MRI (8 studies),
- ³⁹ CT scans (4 studies), and hysteroscopy (1 study). Popular DL models were ResNet, VGGNet, and UNet.



Figure 1: Overview of the diversity and popularity of models used in different studies for the diagnosis of gynecologic cancers

40

- 41 DL algorithms demonstrated high sensitivity (89.40%) but lower specificity (87.6%) compared to
- 42 ML methods, which had lower sensitivity (68.1%) and higher specificity (94.1%). The AUC for DL
- 43 algorithms was 0.88, indicating good diagnostic accuracy. 3D-UNet and EfficientNet-B3 were top-
- ⁴⁴ performing models, with EfficientNet-B3 achieving a classification accuracy of 99.01% for cervical
- 45 cancer detection and 3D-UNet demonstrating high segmentation capabilities with an average Dice Similarity Coefficient (DSC) score of 0.93. Despite the promising results, significant heterogeneity



Figure 2: A Deep learning models used for abnormality detection

and risk of bias were noted, primarily due to variability in patient selection, imaging techniques, and

48 DL model implementation.

49 **4** Conclusion

Deep learning techniques offer substantial improvements in the accuracy and efficiency of diagnosing gynecological cancers using image-based data, surpassing traditional ML methods. However, challenges related to study heterogeneity and model biases need addressing to enhance the clinical applicability of DL models. Future research should focus on refining these algorithms, ensuring their robustness and generalizability, and addressing ethical considerations to fully leverage the potential of DL in gynecological cancer care. Collaborations between researchers, clinicians, and technologists are essential for advancing DL applications in gynecologic cancer diagnostics, ultimately improving

57 early detection and patient outcomes.

58 **References**

[1] Hugo JWL Aerts, Emmanuel Rios Velazquez, Ralph TH Leijenaar, Chintan Parmar, Patrick
 Grossmann, Sara Carvalho, Johan Bussink, René Monshouwer, Benjamin Haibe-Kains, Derek
 Rietveld, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative
 radiomics approach. *Nature communications*, 5(1):4006, 2014.

[2] Rifat Atun, David A Jaffray, Michael B Barton, Freddie Bray, Michael Baumann, Bhadrasain
 Vikram, Timothy P Hanna, Felicia M Knaul, Yolande Lievens, Tracey YM Lui, et al. Expanding
 global access to radiotherapy. *The lancet oncology*, 16(10):1153–1186, 2015.

[3] Marc Brisson, Jane J Kim, Karen Canfell, Mélanie Drolet, Guillaume Gingras, Emily A
 Burger, Dave Martin, Kate T Simms, Élodie Bénard, Marie-Claude Boily, et al. Impact of hpv
 vaccination and cervical screening on cervical cancer elimination: a comparative modelling
 analysis in 78 low-income and lower-middle-income countries. *The Lancet*, 395(10224):575–
 590, 2020.

[4] Thibaud P Coroller, Patrick Grossmann, Ying Hou, Emmanuel Rios Velazquez, Ralph TH
 Leijenaar, Gretchen Hermann, Philippe Lambin, Benjamin Haibe-Kains, Raymond H Mak, and
 Hugo JWL Aerts. Ct-based radiomic signature predicts distant metastasis in lung adenocarci noma. *Radiotherapy and Oncology*, 114(3):345–350, 2015.

- [5] Oraianthi Fiste, Michalis Liontos, Flora Zagouri, Georgios Stamatakos, and Meletios Athanasios
 Dimopoulos. Machine learning applications in gynecological cancer: a critical review. *Critical Reviews in Oncology/Hematology*, 179:103808, 2022.
- [6] Wentian Guo, Hui Li, Yitan Zhu, Li Lan, Shengjie Yang, Karen Drukker, Elizabeth Morris,
 Elizabeth Burnside, Gary Whitman, Maryellen L Giger, et al. Prediction of clinical phenotypes
 in invasive breast carcinomas from the integration of radiomics and genomics data. *Journal of medical imaging*, 2(4):041007–041007, 2015.
- [7] Robert M Haralick and Linda G Shapiro. Image segmentation techniques. *Computer vision, graphics, and image processing*, 29(1):100–132, 1985.
- Philippe Lambin, Emmanuel Rios-Velazquez, Ralph Leijenaar, Sara Carvalho, Ruud GPM
 Van Stiphout, Patrick Granton, Catharina ML Zegers, Robert Gillies, Ronald Boellard, André
 Dekker, et al. Radiomics: extracting more information from medical images using advanced
 feature analysis. *European journal of cancer*, 48(4):441–446, 2012.
- [9] Matthew J Page, Joanne E McKenzie, Patrick M Bossuyt, Isabelle Boutron, Tammy C Hoffmann,
 Cynthia D Mulrow, Larissa Shamseer, Jennifer M Tetzlaff, Elie A Akl, Sue E Brennan, et al.
 The prisma 2020 statement: an updated guideline for reporting systematic reviews. *Bmj*, 372,
 2021.
- [10] Neeraj Sharma and Lalit M Aggarwal. Automated medical image segmentation techniques.
 Journal of medical physics, 35(1):3–14, 2010.
- [11] Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, Mathieu Laversanne, Isabelle Soerjomataram,
 Ahmedin Jemal, and Freddie Bray. Global cancer statistics 2020: Globocan estimates of
 incidence and mortality worldwide for 36 cancers in 185 countries. *CA: a cancer journal for clinicians*, 71(3):209–249, 2021.
- [12] Martin Vallières, Emily Kay-Rivest, Léo Jean Perrin, Xavier Liem, Christophe Furstoss,
 Hugo JWL Aerts, Nader Khaouam, Phuc Felix Nguyen-Tan, Chang-Shu Wang, Khalil Sul tanem, et al. Radiomics strategies for risk assessment of tumour failure in head-and-neck cancer.
 Scientific reports, 7(1):10117, 2017.
- [13] Penny F Whiting, Anne WS Rutjes, Marie E Westwood, Susan Mallett, Jonathan J Deeks,
 Johannes B Reitsma, Mariska MG Leeflang, Jonathan AC Sterne, Patrick MM Bossuyt, and
 QUADAS-2 Group*. Quadas-2: a revised tool for the quality assessment of diagnostic accuracy
 studies. *Annals of internal medicine*, 155(8):529–536, 2011.